EMEA-002226-PIP02-17
Key facts
| Active substance |
Humanized recombinant IgG4 anti-human tau antibody
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0100/2018
|
| PIP number |
EMEA-002226-PIP02-17
|
| Pharmaceutical form(s) |
Concentrate and solvent for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of progressive supranuclear palsy
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
AbbVie Ltd
Tel. +44 07818428129
E-mail: paediatricteam@abbvie.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|